# US 2011/0257105 A1 · Synthetic peptide amides and dimers thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0257105 A1
- Document ID: US20110257105A1
- Status: Published application
- Kind: A1
- Application number: 12/913,363
- Filed: 2010-10-27
- Published: 2011-10-20
- Earliest claimed: 2006-11-10
- Assignees: Cara Therapeutics, Inc.
- Inventors: Claudio D. Schteingart; Frédérique Menzaghi; Guangcheng Jiang; Roberta Vezza Alexander; Javier Sueiras-Diaz; Robert H. Spencer; Derek T. Chalmers; Zhiyong Luo
- Web page: https://patentgrep.com/patent/US20110257105A1

## CPC

- C07K 5/1016: {and aromatic or cycloaliphatic}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 3/12: for electrolyte homeostasis
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/14: Antitussive agents
- A61P 13/12: of the kidneys
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 15/14: for lactation disorders, e.g. galactorrhoea
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/20: Hypnotics; Sedatives
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 5/1005: {and aliphatic}
- C07K 5/1008: {the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala}
- C07K 5/1024: {with the first amino acid being heterocyclic}
- C07K 7/06: having 5 to 11 amino acids
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: The compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.

## Claims

### Claim 1

A synthetic peptide amide having the formula:
or a stereoisomer, mixture of stereoisomers, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, N-oxide or isomorphic crystalline form thereof,
wherein
each Xaa1 is independently selected from the group consisting of (A)(A′)D-Phe, (A)(A′)(α-Me)D-Phe, D-Tyr, D-Tic, D-tert-leucine, D-neopentylglycine, D-phenylglycine, D-homophenylalanine, and β-(E)D-Ala, wherein each (A) and each (A′) are phenyl ring substituents independently selected from the group consisting of —H, —F, —Cl, —NO2, —CH3, —CF3, —CN, —CONH2, and wherein each (E) is independently selected from the group consisting of cyclobutyl, cyclopentyl, cyclohexyl, pyridyl, thienyl and thiazolyl;
each Xaa2 is independently selected from the group consisting of (A)(A′)D-Phe, (A)(A′)(α-Me)D-Phe, D-1Nal, D-2Nal, D-Tyr, (E)D-Ala, and D-Trp;
each Xaa3 is independently selected from the group consisting of D-Nle, D-Phe, (E)D-Ala, D-Leu, (α-Me)D-Leu, D-Hle, D-Val, and D-Met;
each Xaa4 is independently selected from the group consisting of (B)2D-Arg, (B)2D-Nar, (B)2D-Har, ζ-(B)D-Hlys, D-Dap, ε-(B)D-Lys, ε-(B)2-D-Lys, D-Amf, amidino-D-Amf, γ-(B)2D-Dbu, δ-(B)2α-(B′)D-Orn, D-2-amino-3(4-piperidyl)propionic acid, D-2-amino-3(2-aminopyrrolidyl)propionic acid, D-α-amino-β-amidino-propionic acid, α-amino-4-piperidineacetic acid, cis-α,4-diaminocyclohexane acetic acid, trans-α,4-diaminocyclohexaneacetic acid, cis-α-amino-4-methyl-aminocyclo-hexane acetic acid, trans-α-amino-4-methylaminocyclohexane acetic acid, α-amino-1-amidino-4-piperidineacetic acid, cis-α-amino-4-guanidino-cyclohexane acetic acid, and trans-α-amino-4-guanidinocyclohexane acetic acid, wherein each (B) is independently selected from the group consisting of —H and C1-C4 alkyl, and (B′) is —H or (α-Me), and p is zero or 1;
G is selected from one of the following moieties:
(i) G is
wherein
q is zero or 1;
r is zero or 1;
s is zero or 1;
p and t are each independently zero or 1, provided that at least one of q, r, s and t is 1;
L is a linker selected from the group consisting of ε-D-Lys, ε-Lys, δ-D-Orn, δ-Orn, γ-aminobutyric acid, 8-aminooctanoic acid, 11-amino-undecanoic acid, 8-amino-3,6-dioxaoctanoic acid, 4-amino-4-carboxylic piperidine and (D-Lys-Gly lactam)2;
(ii) G is
wherein p is 1;
Xaa3-Xaa4- is selected from the group consisting of D-Nle-(B)2D-Arg-, D-Leu-δ-(B)2α-(B′)D-Orn-, and (α-Me)D-Leu-δ(B)2-α(B′)D-Orn-; and
the moiety
is an optionally substituted 4 to 8-membered heterocyclic ring moiety wherein all ring heteroatoms in said ring moiety are N; wherein Y and Z are each independently C or N; provided that when such ring moiety is a six, seven or eight-membered ring, Y and Z are separated by at least two ring atoms; and provided that when such ring moiety has a single heteroatom which is N, then such ring moiety is non-aromatic;
(iii) G is
wherein p is 1; and
the moiety
is an optionally substituted 4 to 8-membered heterocyclic ring moiety wherein Y is C or N and Z is C, N, O, S, SO, or SO2; provided that when such ring moiety is a six-, seven- or eight-membered ring, Y and Z are separated by at least two ring atoms; provided that when such ring moiety is non-aromatic and Z is C or N then such ring moiety comprises at least one S or O ring heteroatom; and provided further that when such ring moiety is aromatic, then Y is C;
and
(iv) G is
wherein J is a 5-, 6-, or 7-membered heterocyclic ring moiety comprising 1, 2, or 3 heteroatoms in the ring wherein R3 and R4 are each independently selected from C1-C3 alkyl, halo, —OH, —CF3, —NH2, —COOH and amidino; and R5 and R6 are each independently selected from C1-C3 alkyl, oxo, halo, —OH, —CF3, —NH2, —COOH and amidino;
wherein W and W′ are selected from the group consisting of:
null, provided that when W is null, Y is N;
—NH—(CH2)b— with b equal to zero, 1, 2, 3, 4, 5, or 6; and
—NH—(CH2)cO— with c equal to 2, or 3;
wherein V is C1-C6 alkyl, and e is zero or 1, wherein when e is zero, then V is null and, R1 and R2 are directly bonded to the same or different ring atoms;
wherein
(a) R1 is —H, —OH, halo, CF3, —NH2, —COOH, C1-C6 alkyl, amidino, C1-C6 alkyl-substituted amidino, aryl, optionally substituted heterocyclyl, Pro-amide, Pro, Gly, Ala, Val, Leu, Ile, Lys, Arg, Orn, Ser, Thr, CN, CONH2, COR′, SO2R′, CONR′R″, NHCOR′, OR′, or SO2NR′R″; wherein said optionally substituted heterocyclyl is optionally singly or doubly substituted with substituents independently selected from the group consisting of C1-C6 alkyl, —C1-C6 alkoxy, oxo, —OH, —Cl, —F, —NH2, —NO2, —CN, —COOH, and amidino; wherein R′ and R″ are each independently —H, C1-C8 alkyl, aryl, heterocyclyl or R′ and R″ are combined to form a 4- to 8-membered ring, which ring is optionally substituted singly or doubly with substituents independently selected from the group consisting of C1-C6 alkyl, —C1-C6 alkoxy, —OH, —Cl, —F, —NH2, —NO2, —CN, —COOH and amidino; and R2 is H, amidino, singly or doubly C1-C6 alkyl-substituted amidino, —CN, —CONH2, —CONR′R″, —NHCOR′, —SO2NR′R″, or —COOH; or
(b) R1 and R2 taken together can form an optionally substituted 4- to 9-membered heterocyclic monocyclic or bicyclic ring moiety which is bonded to a single ring atom of the Y and Z-containing ring moiety; or
(c) R1 and R2 taken together with a single ring atom of the Y and Z-containing ring moiety can form an optionally substituted 4- to 8-membered heterocyclic ring moiety to form a spiro structure; or
(d) R1 and R2 taken together with two or more adjacent ring atoms of the Y and Z-containing ring moiety can form an optionally substituted 4- to 9-membered heterocyclic monocyclic or bicyclic ring moiety fused to the Y and Z-containing ring moiety;
wherein each of said optionally substituted 4- to 9-membered heterocyclic ring moieties comprising R1 and R2 is optionally singly or doubly substituted with substituents independently selected from the group consisting of C1-C6 alkyl, —C1-C6 alkoxy, optionally substituted phenyl, oxo, —OH, —Cl, —F, —NH2, —NO2, —CN, —COOH, and amidino;
provided that when the Y and Z-containing ring moiety is a six or seven membered ring comprising a single ring heteroatom and when one of Y and Z is C and the other of Y and Z is N, and e is zero, then R1 is not —OH, and R1 and R2 are not both —H;
provided further that when the Y and Z-containing ring moiety is a six membered ring comprising two ring heteroatoms, both Y and Z are N, W is null, and —Ve(R1)(R2) is attached to Z, then —Ve(R1)(R2) is selected from the group consisting of amidino, C1-C6 alkyl-substituted amidino, dihydroimidazole, —CH2COOH, and —H2C(O)NH2; and
lastly, provided that if the Y and Z-containing ring moiety is a six membered ring comprising an S or O ring heteroatom, or if the Y and Z-containing ring moiety is a six membered ring comprising two ring heteroatoms, wherein both Y and Z are N and W is null, or if the Y and Z-containing ring moiety is a six membered aromatic ring comprising a single ring heteroatom, which heteroatom is N, then, when e is zero, R1 and R2 are not both —H.

### Claim 2 (depends on 1)

The synthetic peptide amide of claim 1 wherein G is
wherein p, q, r, s and t are each 1.

### Claim 3 (depends on 1)

The synthetic peptide amide of claim 1 wherein G is
and L is a linker selected from the group consisting of ε-D-Lys, ε-Lys, δ-D-Orn, δ-Orn, 4-amino-4-carboxylic piperidine and (D-Lys-Gly lactam)2.

### Claim 4 (depends on 1)

The synthetic peptide amide of claim 1 wherein G is

### Claim 5 (depends on 4)

The synthetic peptide amide of claim 4 wherein J is a 5-, 6-, or 7-membered heterocyclic ring moiety comprising 1, 2, or 3 heteroatoms in the ring wherein R3 and R4 are each independently selected from C1-C3 alkyl, halo, —OH, —CF3, —NH2, —COOH and amidino; and R5 and R6 are each independently selected from C1-C3 alkyl, oxo, halo, —OH, —CF3, —NH2, —COOH and amidino.

### Claim 6 (depends on 1)

The synthetic peptide amide of claim 1 wherein G is

### Claim 7 (depends on 6)

The synthetic peptide amide of claim 6 wherein W is null, Y is N and Z is C.

### Claim 8 (depends on 6)

The synthetic peptide amide of claim 6 wherein the Y and Z-containing ring moiety is a six-membered saturated ring comprising a single ring heteroatom.

### Claim 9 (depends on 6)

The synthetic peptide amide of claim 6 wherein Y and Z are both N and are the only ring heteroatoms in the Y and Z-containing ring moiety.

### Claim 10 (depends on 9)

The synthetic peptide amide of claim 9 wherein e is zero and R1 and R2 taken together with zero, one or two ring atoms of the Y and Z-containing ring moiety comprise a monocyclic or bicyclic 4-9 membered heterocyclic ring moiety.

### Claim 11 (depends on 9)

The synthetic peptide amide of claim 9 wherein R1 and R2 taken together with one ring atom of the Y and Z-containing ring moiety comprise a 4- to 8-membered heterocyclic ring moiety which with the Y and Z-containing ring moiety forms a spiro structure and W is null.

### Claim 12 (depends on 6)

The synthetic peptide amide of claim 6 wherein e is zero and R1 and R2 are bonded directly to the same ring atom.

### Claim 13 (depends on 6)

The synthetic peptide amide of claim 6, wherein R1 is H, OH, —NH2, —COOH, —CH2COOH, C1-C3 alkyl, amidino, C1-C3 alkyl-substituted amidino, dihydroimidazole, D-Pro, D-Pro amide, or CONH2 and wherein R2 is H, —COOH, or C1-C3 alkyl.

### Claim 14 (depends on 6)

The synthetic peptide amide of claim 6, wherein the moiety:
is selected from the group consisting of:

### Claim 15 (depends on 6)

The synthetic peptide amide of claim 6, wherein the moiety:
is selected from the group consisting of:

### Claim 16 (depends on 1)

The peptide amide of claim 1 having a structure selected from the group consisting of:
1N,4N-bis-[D-Phe-D-Phe-D-Leu-(iPr)D-Orn]-4-amino-4-carboxylic piperidine,
1N,4N-bis-[D-Phe-D-Phe-D-Leu-D-Dap(Amidino)]-4-amino-4-carboxylic piperidine,
1N,4N-bis-(D-Phe-D-Phe-D-Leu-D-Nar)-4-amino-4-carboxylic piperidine,
and

### Claim 17 (depends on 1)

The peptide amide of claim 1, wherein the moiety
is an optionally substituted 4 to 8-membered heterocyclic ring moiety wherein Y is carbon or nitrogen and Z is carbon, nitrogen, oxygen, sulfur, sulfoxide, or sulfonyl.

### Claim 18 (depends on 1)

The synthetic peptide amide according to claim 1, having an EC50 of less than about 500 nM for a kappa opioid receptor.

### Claim 19 (depends on 1)

The synthetic peptide amide according to claim 1, which at an effective concentration exhibits no more than about 50% inhibition of any of P450 CYP1A2, CYP2C9, CYP2C19 or CYP 2D6 by the synthetic peptide amide at a concentration of 10 uM after 60 minutes incubation with human liver microsomes.

### Claim 20 (depends on 1)

The synthetic peptide amide according to claim 1, which at a dose of about 3 mg/kg in rat reaches a peak plasma concentration of the synthetic peptide amide and exhibits at least about a five fold lower concentration in brain than such peak plasma concentration.

### Claim 21 (depends on 15)

The synthetic peptide amide according to claim 15, having an ED50 for a sedative effect in a locomotion-reduction assay in a mouse at least about ten times the ED50 of the synthetic peptide amide for an analgesic effect in a writhing assay in a mouse.

### Claim 22 (depends on 1)

The synthetic peptide amide according to claim 1, having at least about 50% of maximum efficacy at about 3 hours post administration of a dose of about 3 mg/kg of the synthetic peptide amide in a rat.

### Claim 23 (depends on 1)

A pharmaceutical composition comprising the synthetic peptide amide according to claim 1 and a pharmaceutically acceptable excipient or carrier.

### Claim 24 (depends on 1)

A method of treating or preventing a kappa opioid receptor-associated disease or condition in a mammal, the method comprising administering to the mammal a composition comprising an effective amount of a synthetic peptide amide according to claim 1.
